A View on the EU Critical Medicines Act to secure Pharma Supply Chains
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
An article from Bird & Bird, titled "Europe's medicine supply crisis: How the EU's bold new act aims to address supply chain vulnerabilities," discusses the European Union's proposed Critical Medicines Act (CMA), introduced in March 2025. This legislative initiative aims to tackle persistent medicine shortages and reduce the EU's reliance on non-EU countries for pharmaceutical production.
The EU has faced ongoing medicine shortages, exacerbated by the COVID-19 pandemic and geopolitical tensions. These issues have highlighted the risks of dependency on third-country manufacturing, particularly for critical medicines.
The article describes in a comprehensive way background, scope and key elements of the CMA and emphasizes that the CMA represents a significant shift in EU pharmaceutical policy, moving beyond regulatory measures to include industrial policy tools aimed at ensuring medicine availability and supply chain resilience.
For a more detailed analysis, you can read the full article here.
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?